Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy

Approximately 65% of Patients Do Not Have Targetable Genetic Mutations

Centurion BioPharma, Owns a Pipeline of Drug Candidates That Have the Potential to Improve Efficacy and Safety of Chemotherapy by Targeting Ultra-High Potency Drug Delivery Directly Inside the Tumor

LOS ANGELES – February 11, 2019 – Centurion BioPharma highlighted comments from an OncLive® article dated February 1, 2019 that an estimated majority of oncology patients do not have targetable genetic mutations that would make them eligible for targeted treatment. Therefore, this majority of patients are candidates for standard therapies, which typically include chemotherapy.

Dr. Keith T. Flaherty, ECOG-ACRIN study chair and a medical oncologist at Massachusetts General Hospital Cancer Center, noted in the OncLive® article that it appears roughly 65% of patients do not have potentially targetable mutations. While progress has been made in some areas for patients with genetic mutations, and studies like NCI-MATCH (a precision medicine trial of numerous agents across tumor types) continue to assess which patients may benefit from therapies targeting certain genes, for the majority of cancer patients, there is no targetable genetic mutations.

Centurion BioPharma is focused on advancing the albumin binding ultra-high potency LADR™ (Linker-Activated Drug Release) oncology drug candidates and accompanying companion diagnostic (ACDx) to improve clinical outcomes for patients with solid tumors.

“Because the majority of cancer patients do not have a targetable genetic mutation, CytRx believes many of those patients may be candidates for chemotherapy. Conventional chemotherapy agents have been a mainstay in standard oncology practice for decades and remains the relevant approach for the majority of physicians and patients,” Eric Curtis, President and CEO of Centurion Corporation. “We believe that our LADR assets and accompanying ACDx will greatly improve the safety and efficacy of cytotoxic therapy, leading to better clinical outcomes across a wide variety of solid tumor types. The ability of LADR to maximize tumor cell kill potential, while minimizing systemic toxicity, means these assets can fulfill a significant clinical unmet need. Additionally, our companion diagnostic shows promise to increase the value of the LADR pipeline by incorporating a personalized medicine approach.”

About Centurion BioPharma Corporation

Centurion BioPharma Corporation, is focused on the development of personalized medicine that is designed to transform solid tumor treatment. This transformational strategy combines a portfolio of novel, anti-cancer drug candidates that employ LADR™ (Linker Activated Drug Release) technology, a discovery engine designed to leverage Centurion's expertise in albumin biology and linker technology for the development of a new class of breakthrough anti-cancer therapies with a unique albumin companion diagnostic (ACDx) that can help identify patients who are most likely to benefit from treatment with the LADR™-derived therapies. A critical element of the LADR™ platform is its ability to bind anti-cancer molecules to circulating albumin, the most ubiquitous protein in human blood plasma, and then to release the highly potent cytotoxic payload at the tumor site. This technology allows for the delivery of higher doses of drug directly to the tumor, while avoiding much of the off-target toxicity
Observed with the patent molecules. Centurion BioPharma Corporation's website is www.centurionbiopharma.com.

Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com

# # #